PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q3 2023. The put-call ratio across all filers is - and the average weighting 4.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,824 | – | 2,579 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $57,834,000 | 8.52% |
| venBio Partners LLC | 2,303,310 | $40,838,000 | 4.07% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $56,392,000 | 3.50% |
| Foresite Capital Management V, LLC | 364,142 | $6,456,000 | 2.01% |
| VR Adviser, LLC | 552,882 | $9,803,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,608,471 | $28,518,000 | 0.56% |
| Cormorant Asset Management, LP | 689,731 | $12,229,000 | 0.50% |
| Novo Holdings A/S | 418,943 | $7,428,000 | 0.38% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $42,909,000 | 0.25% |
| DAFNA Capital Management LLC | 35,074 | $622,000 | 0.16% |